Mutual of America Capital Management LLC Has $6.29 Million Stock Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Mutual of America Capital Management LLC increased its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 49.8% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 32,030 shares of the medical research company’s stock after purchasing an additional 10,655 shares during the period. Mutual of America Capital Management LLC’s holdings in IQVIA were worth $6,294,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in the business. FMR LLC grew its stake in IQVIA by 38.7% during the third quarter. FMR LLC now owns 2,887,342 shares of the medical research company’s stock worth $684,213,000 after purchasing an additional 804,963 shares during the period. JPMorgan Chase & Co. grew its stake in IQVIA by 46.2% during the third quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock worth $437,378,000 after purchasing an additional 583,396 shares during the period. Impax Asset Management Group plc grew its stake in IQVIA by 9.7% during the third quarter. Impax Asset Management Group plc now owns 1,793,010 shares of the medical research company’s stock worth $423,885,000 after purchasing an additional 157,809 shares during the period. Nordea Investment Management AB grew its stake in IQVIA by 47.4% during the fourth quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock worth $277,908,000 after purchasing an additional 452,029 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in IQVIA by 3.4% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,226,083 shares of the medical research company’s stock worth $290,545,000 after purchasing an additional 39,772 shares during the period. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Stock Down 2.2 %

IQV stock opened at $184.67 on Tuesday. IQVIA Holdings Inc. has a twelve month low of $184.06 and a twelve month high of $261.73. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12. The stock’s 50 day moving average is $198.84 and its 200-day moving average is $214.25. The firm has a market capitalization of $32.52 billion, a PE ratio of 24.62, a P/E/G ratio of 1.99 and a beta of 1.48.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. Sell-side analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms recently commented on IQV. Bank of America decreased their target price on IQVIA from $255.00 to $235.00 and set a “buy” rating for the company in a research note on Friday, December 13th. Stifel Nicolaus cut their price target on IQVIA from $273.00 to $261.00 and set a “buy” rating on the stock in a report on Friday, February 7th. BTIG Research lowered IQVIA from a “buy” rating to a “neutral” rating in a report on Monday, February 3rd. Stephens assumed coverage on IQVIA in a report on Friday, December 20th. They issued an “overweight” rating and a $250.00 price target on the stock. Finally, Robert W. Baird cut their price target on IQVIA from $212.00 to $210.00 and set a “neutral” rating on the stock in a report on Tuesday, January 21st. Four equities research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, IQVIA currently has an average rating of “Moderate Buy” and an average price target of $251.22.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.